CommentThe African Network for Drugs and Diagnostics Innovation
References (7)
Part I: health product R&D landscape in Africa, and Part 2: collection of meeting abstract. Founding meeting in Abuja, Nigeria
Global strategy and plan of action on public health, innovation and intellectual property
Bamako call to Action: research for health
Lancet
(2008)
Cited by (33)
China-Africa cooperation initiatives in malaria control and elimination
2014, Advances in ParasitologyCitation Excerpt :As many pharmaceutical companies in China have certain capabilities for developing new antimalarial drugs (Chen, 2014), there is an urgent need for the transformation of current approaches that address these candidate traditional medicines in Africa, in a manner that strengthens South–South collaborations and translates stagnating African discoveries into usable and accessible health tools. This China–Africa partnership presents a real opportunity to advance this area and build relevant capacity (Dawson et al., 2014; Mboya-Okeyo et al., 2009; Nwaka et al., 2010; Thorsteinsdottir et al., 2010; Uwimana et al., 2012). Over the past 60 years, P. R. China has made remarkable achievements in malaria control in terms of very limited local transmission and is proceeding with malaria elimination.
Drugs and diagnostic innovations to improve global health
2011, Infectious Disease Clinics of North AmericaCitation Excerpt :WHO’s Global Strategy and Plan of Action developed by the Inter-Governmental Working Group on Innovation, Intellectual Property and Public Health promotes innovation as a way to improve R&D, access, and build sustainable capacity in developing countries for a range of affordable interventions for diseases that disproportionately affect developing countries.13 The African Network for Drugs and diagnostics Innovation (ANDI) has been established to help build a sustainable platform for R&D innovation in Africa.23,24 This landmark initiative is already establishing pan-African Centers of Excellence to support product R&D and access in Africa, the first of its kind in Africa.
Proteomics of foodborne trematodes
2011, Journal of ProteomicsCitation Excerpt :There has been little incentive to invest in the discovery and development of trematodicidal drugs. While public–private partnerships work for some of the neglected tropical diseases since 1999 (e.g. the Drugs for Neglected Diseases Initiative (DNDi) focusing on human African trypanosomiasis and leishmaniasis), pioneering programmes for major helminth diseases are underway [14,15]. In this context, studies to identify new and specific targets for treatment are needed.
Diagnostics as essential tools for containing antibacterial resistance
2011, Drug Resistance UpdatesCitation Excerpt :Currently, there is insufficient exchange between the public and the private sector, or among diagnostic and pharmaceutical industries. Recent public-private initiatives have resulted in product development partnerships, such as those described in Box 1, may address some of these issues (Hunter, 2008; Mboya-Okeyo et al., 2009). A recent call for proposals from the Bill & Melinda Gates Foundation and Grand Challenges Canada, aims to overcome the problems associated with linking different innovations by allocating funds for component building in phase 1 and then funding a second phase to support integration of the “best-in-class” from each component (Box 1).
Point-of-care tests for diagnosing infections in the developing world
2010, Clinical Microbiology and InfectionCitation Excerpt :The product pipeline of diagnostics for infectious diseases of public health importance in the developing world is weak, as large diagnostics companies have shown little interest, and companies in the developing world generally do not have sufficient research funding or expertise. The WHO/TDR has recently initiated an African Network for Drugs and Diagnostics Innovation, aimed at promoting and building research and development capacity for target discovery and product development [51]. This initiative is supported by the WHO/TDR, the African Development Bank, the European Union, pharmaceutical companies, and governments in the region.